ArticleOncoTargets and therapy2026

Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report.

An-Fu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.